Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are growth factors leukemogenic?

R A Brodsky1, A Bedi, R J Jones

  • 1Johns Hopkins Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Leukemia
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Layer + Model: Incorporating Psychosocial Considerations into Hip Preservation Surgery.

Current reviews in musculoskeletal medicine·2025
Same author

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Cancer Trial Impact: Understanding Implementation of the Short Course Oncology Treatment (SCOT) Trial Findings in colorectal cancer at a National Level.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Using diffusion MRI data acquired with ultra-high gradient strength to improve tractography in routine-quality data.

NeuroImage·2021
Same author

Fermentative volatile fatty acid production and recovery from grass using a novel combination of solids separation, pervaporation, and electrodialysis technologies.

Bioresource technology·2021
Same author

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
See all related articles

Patients on a NCI trial for breast cancer may face a higher risk of secondary acute myeloid leukemia (AML). This risk might be linked to hematopoietic growth factors interfering with chemotherapy-induced cell death, promoting leukemic transformation.

Area of Science:

  • Oncology
  • Hematology
  • Cancer Therapeutics

Background:

  • A National Cancer Institute (NCI) trial identified a potential increased risk of secondary acute myeloid leukemia (AML) in breast cancer patients.
  • Standard doses of doxorubicin and cyclophosphamide are rarely associated with secondary AML, suggesting trial-specific factors are involved.

Purpose of the Study:

  • To investigate the potential causes of secondary AML observed in patients on a specific NCI-sponsored cooperative group trial.
  • To explore the role of hematopoietic growth factors in the development of secondary AML following adjuvant chemotherapy.

Main Methods:

  • Analysis of patient data from an NCI-sponsored cooperative group trial for breast cancer.
  • Review of secondary AML case characteristics and their association with specific chemotherapeutic agents and growth factors.

Related Experiment Videos

Main Results:

  • Observed secondary AML cases were characteristic of those linked to topoisomerase II-active agents, though not typically associated with doxorubicin or cyclophosphamide.
  • The study posits that hematopoietic growth factors, used to mitigate myelosuppression, may contribute to leukemic transformation by inhibiting apoptosis in damaged hematopoietic progenitors.

Conclusions:

  • Higher-than-standard chemotherapy doses may not solely explain the elevated risk of secondary AML.
  • Hematopoietic growth factors' role in suppressing apoptosis of chemotherapy-damaged cells is a potential mechanism driving leukemic transformation in this trial setting.